Abstract: The present invention is directed to peptides comprising the sequence ASNKL (SEQ ID No. 1), inducing attraction of the axonal growth in presence of the semaphorin (Sema3A), L1 and NP-1 proteins and their use for the manufacture of a drug for neuronal/axonal regeneration or for treating neurodegenerative diseases. The present invention also includes a method for identifying a compound able to bind the NP-1, a method for identifying a compound able to revert the repulsory effect of Sema3A on the axonal growth from a suited cell, or methods to screen for molecules capable of blocking Sema3A-induced endocytosis.